Buserelin Acetate (Suprefact®)

Buserelin Acetate (SuCommon name: Buserelin Acetate
Brand name: Suprefact®


What is Buserelin Acetate?

Buserelin Acetate is a luteinizing hormone releasing hormone (LHRH) analogue that is used in the palliative treatment of advanced (metastatic) prostate cancer. Buserelin acetate works by blocking the production of testosterone which reduces the growth and reproduction of prostate cancer cells.
 

How is Buserelin Acetate administered?

Buserelin Acetate is by administered by subcutaneous injection or as a nasal solution.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received buserelin acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
 
  • Diarrhea
  • Dizziness
  • Dry mouth
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Nausea / vomiting
  • Reduced sexual desire (low libido)


Is Buserelin Acetate covered in my province or territory?

Buserelin acetate is covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • Manitoba
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Ontario
  • Quebec
  • Saskatchewan
  • Nunavut
  • Northwest Territories
  • Yukon
Buserelin acetate is not covered by provincial drug programs in:
  • Prince Edward Island
 
Last Reviewed: July 2017

 
   
   

Donate Now!






Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive